A federal judge in Virginia has thrown out Johnson & Johnson’s trade libel lawsuit against three doctors who published research on mesothelioma patients whose only known asbestos exposure was cosmetic talc. The court found the company could not show the researchers published anything knowing it was false or while seriously doubting it was true. The case was dismissed on summary judgment before it reached a jury.
What did the judge decide?
U.S. District Judge Jamar K. Walker granted summary judgment to Drs. Theresa Emory, John Maddox, and Richard Kradin, and denied the matching motion filed by Pecos River Talc LLC, the Johnson & Johnson subsidiary that brought the case in the Eastern District of Virginia.
The claim was trade libel, also called product disparagement. That framing matters. The company was not suing to protect a person’s reputation. It was suing to protect a product, and to win it had to prove by clear and convincing evidence that the doctors published a false statement of fact with actual malice, meaning they knew it was false or published while seriously doubting whether it was true. That standard comes from New York Times v. Sullivan and applies to speech on matters of public debate.
The court found the evidence went the other way. Walker pointed to proof that the researchers had taken deliberate steps to build the study correctly, screening out patients who had appeared in an earlier paper and patients with conventional asbestos exposure histories. Years of discovery aimed at the authors’ methods and correspondence surfaced some discrepancies, but the judge found nothing indicating the authors were aware of a problem and published anyway. An incomplete investigation, he concluded, is not the same thing as a knowing falsehood, and the company had not come close to the standard the law requires.
Why did Johnson & Johnson sue three doctors?
Because the science has not gone the company’s way in front of juries.
Pecos River Talc exists as a product of Johnson & Johnson’s effort to route talc liability through bankruptcy court. When that effort collapsed for the third time in Texas in 2025, the entity was left handling mesothelioma claims in the ordinary court system, which is exactly where the company had spent years trying not to be. Suing the researchers pursues the same objective by other means. If published work connecting cosmetic talc to mesothelioma could be branded as knowingly false, the experts who rely on it become far easier to attack in every individual case.
A parallel suit against Dr. Jacqueline Moline, who published earlier research on the same question, remains pending.
Our ongoing coverage of the J&J talc litigation
This ruling is the latest turn in a case we have followed since 2025:
- Johnson & Johnson’s $10 Billion Talc Settlement Faces Pivotal Bankruptcy Trial (February 2025) covers the Houston bankruptcy hearing and the objections raised against the plan.
- Johnson & Johnson’s Talc Bankruptcy Settlement Under Scrutiny as Trial Concludes (March 2025) walks through the Texas Two-Step and what was at stake as testimony wrapped.
- Johnson & Johnson Talc Bankruptcy Rejected explains Judge Christopher Lopez’s March 31, 2025 decision dismissing the case and returning claims to the trial courts.
- Minnesota Jury Orders Johnson & Johnson to Pay $65.5 Million in Talc Cancer Lawsuit (December 2025) shows what happened once mesothelioma cases started reaching juries again.
What was in the 2020 study?
Emory, Maddox, and Kradin published a case series in the American Journal of Industrial Medicine in March 2020 describing 75 people diagnosed with malignant mesothelioma whose only identified asbestos exposure came from cosmetic talc products.
Talc and asbestos are not neighbors in the ground. They are intergrown. Both form under the same metamorphic conditions, and tremolite and anthophyllite have been found in talc ore, in talc products, and in the lungs of the people who mined and milled it. Mesothelioma rates among talc miners and millers in New York State have been documented well above the general population.
The company’s position throughout has been that its talc has never contained asbestos and has never caused cancer. The scientific bodies have moved the other direction. The World Health Organization’s International Agency for Research on Cancer classifies talc as probably carcinogenic to humans, and the definition it used covers both the lamellar and the fibrous forms of the mineral. Talc containing asbestos has been classified as carcinogenic to humans for decades.
In an individual case, the defense argument is almost always that the person picked up their exposure somewhere else, at work, in an old building, or from a family member’s clothing. A documented series of patients with no such alternative source is difficult evidence for a talc defendant to answer, which is precisely why the company went after it.
Johnson & Johnson alleged in its complaint that some of the 75 patients had other exposures and that some had appeared in earlier published work. Those allegations were tested through full discovery, and the court found they did not establish what the company needed them to establish.
Did the court decide the science?
It did not, and it is worth knowing who kept it out.
The doctors moved to compel discovery into whether repeated exposure to cosmetic talc can cause mesothelioma. They wanted the causation evidence in front of the court. Johnson & Johnson resisted. The court agreed the question was not relevant to a narrow trade libel claim and denied the motion, and the record reflects that the company was not arguing in that proceeding that its products were free of asbestos or that talc cannot cause mesothelioma. It argued only that those questions did not belong in this particular lawsuit.
A company that has spent years telling the public its talc is safe filed a case about that very question and then worked to keep the question out of it. Causation stays where it has always been, in individual trials, in front of juries who have repeatedly found for plaintiffs.
What does this mean for people diagnosed with mesothelioma after using talc products?
The research stands. It remains published, remains citable, and remains available to the experts who testify in these cases. An attempt to strip it out of the litigation and to put a price on the careers of the people who produced it has failed.
Nothing about any individual claim changed. This ruling did not create or remove a legal right and did not alter a filing deadline.
One point causes recurring confusion. Johnson & Johnson’s proposed settlement announced in July 2026 covers ovarian cancer claims. Mesothelioma claims are not part of it. Settlement headlines lead people to assume the talc litigation is over, and it is not. Mesothelioma cases have continued to be tried and continued to produce verdicts through 2026.
Filing deadlines are set by state law, vary considerably, and generally run from diagnosis rather than from when a product was used. That distinction matters here, because talc exposure often dates back decades while mesothelioma typically surfaces twenty to fifty years later.
What happens next?
Pecos River can appeal to the Fourth Circuit, and the company has appealed nearly every adverse ruling in this litigation. The Moline suit is still live. And the question the company avoided in Virginia, whether the talc a particular person used caused their mesothelioma, keeps getting answered one courtroom at a time.
